查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1654430

單核細胞活化分析市場規模、佔有率、趨勢分析報告：按產品、來源、最終用途、地區和細分市場進行預測，2025 年至 2030 年

Monocyte Activation Test Market Size, Share & Trends Analysis Report By Product (MAT Kits, Reagents), By Source (PBMC Based, Cell Line Based), By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10個工作天內

價格

單核細胞活化試驗 (MAT) 市場成長與趨勢

根據Grand View Research, Inc.的最新報告，全球單核細胞活化測試市場規模預計到2030年將達到14.5億美元，2025年至2030年期間的複合年成長率為15.9%。

市場受到幾個關鍵因素的驅動。越來越大的監管壓力要求以更符合道德、更適合人類的體外方法取代動物試驗，這是一個主要促進因素。 MAT 利用人體免疫細胞進行精確的熱原檢測能力使其成為傳統內毒素檢測的一種有吸引力的替代方案。對生技藥品、疫苗和複雜藥物的需求不斷成長，進一步推動了 MAT 的採用，因為這些產品的安全性至關重要。此外，生物技術的進步以及對病人安全和藥物開發品管的日益重視也促進了市場的成長。

技術創新正在推動單核細胞活化測試市場的成長。其中一個重大進展是創建更有效率、更可重複的細胞培養系統，特別是使用永生化人類細胞株，如 THP-1 和 U937 細胞。這些細胞株提高了 MAT 的精確度和一致性，使其成為傳統動物測試方法的更可靠替代方案。使用這些細胞株模擬人體免疫反應的能力提高了 MAT 的靈敏度，從而可以更好地檢測熱原（包括內毒素和非內毒素）。

另一項創新是 MAT 流程的自動化，它簡化了測試工作流程並減少了獲得結果所需的時間。 MAT 樣品製備和分析的自動化系統正在提高吞吐量，使得大型製藥和生物技術公司更有能力將 MAT 納入其品管流程。 Minerva Biolabs 的下一代 MAT 系統 N​​AT-MAT​​ 代表了熱原測試的重大進步。透過利用數位 PCR 測量 IL-1B 和 TNF-a 的基因表現，NAT-MAT​​ 對檢測內毒性和非內毒性熱原提供了高度靈敏和可靠的結果。該系統針對快速測試進行了最佳化，並符合 Ph. Eur. 2.6.30 標準。

NAT-MAT​​® 的關鍵創新是同時測量兩種細胞激素和管家基因，從而提高結果的準確性。管家基因作為萃取過程和細胞密度的品管，以確保該檢測在不同細胞密度下可靠地進行。此外，使用 Minerva Biolabs 專有軟體進行自動分析可簡化流程並提高測試效率，同時確保符合法規要求。

該技術比傳統的熱原檢測方法有了顯著的改進，提供了更全面、更準確的方法來確保藥品和生物技術產品的安全。例如，Lonza Group 和 Charles River Laboratories 等公司正在將先進的細胞培養技術和自動化系統整合到其 MAT 產品中，以提高效率和可擴展性。此外，高通量和篩檢技術的進步使得熱原檢測更快、更具成本效益，使 MAT 在藥物開發和疫苗製造中得到更廣泛的應用。這些創新持續促進 MAT 的廣泛使用，使其成為確保藥品和生技產品安全性和有效性的重要工具。

單核細胞活化測試市場報告重點

  • 按產品分類，MAT套件部門在 2024 年佔據最大的收入佔有率，為 63.7%。由於對可靠的人體相關熱原檢測方法的需求不斷增加，MAT套件領域正在經歷成長。一個主要的促進因素是不斷增加的監管壓力，要求用試管內試驗取代動物試驗。 MAT套件利用人體免疫細胞檢測內毒素和非內毒素熱原，提供了準確、道德的解決方案，確保藥物安全。此外，生技藥品、疫苗和複雜藥物製劑的日益普及也推動了對 MAT套件的需求。這些產品必須經過嚴格的安全測試才能進入市場。 MAT套件的便利性和準確性進一步促進了其被採用。
  • 作為動物試驗的替代品，對符合道德的人體試驗的需求不斷成長，導致 PBMC 佔據了市場主導地位，到 2024 年佔據 62.7% 的最大佔有率。 PBMCs 含有單核細胞，對於熱原檢測至關重要，因為它們與人類的免疫反應非常相似。這種與人類相關的測試方法正在獲得支持，因為與傳統動物模型相比，它可以提供更準確和可重複的結果。此外，生技藥品的發展、疫苗可用性的增加以及用試管內方法取代動物測試的監管壓力進一步推動了基於 PBMC 的 MAT 測試的採用。
  • 根據應用，由於對準確可靠的熱原檢測方法的需求不斷增加，藥物開發將佔據市場主導地位，到 2024 年將佔據 40.6% 的最大佔有率。隨著製藥業開發出更複雜的生技藥品和疫苗，透過嚴格的測試確保這些產品的安全至關重要。 MAT 描述了一種體外、與人類相關的檢測內毒素和非內毒素熱原的方法，取代了傳統的動物測試方法。 FDA 和 EMA 等監管機構已核准MAT 作為有效的替代方案，進一步鼓勵其在藥物開發中的應用。越來越關注病人安全、法規遵循和對更快測試方法的需求是關鍵促進因素。
  • 根據最終用途，製藥業將在 2024 年佔據最大的市場佔有率，達到 56.3%。市場成長的驅動力是藥品開發和製造過程中對可靠的熱原測試的日益成長的需求。由於該行業專注於生產生技藥品、疫苗和其他複雜的治療產品，因此確保它們的安全至關重要。 MAT 可使用人體免疫細胞檢測內毒素和非內毒素熱原，是一種準確且合乎道德的傳統動物測試替代方法。 FDA 和 EMA 等監管機構支持使用 MAT 並鼓勵其採用。製藥製造業對更安全、更快捷、更有效的測試方法的需求日益成長，是推動 MAT 市場成長的主要因素。
  • 北美在全球市場佔據主導地位的關鍵因素是該地區嚴格的法規環境，FDA 和加拿大衛生署等機構擴大支持 MAT 作為傳統動物試驗的可靠且合乎道德的替代方案。生技藥品和疫苗領域的成長也推動了對 MAT 的需求，因為確保產品安全至關重要。此外，對病人安全的日益關注、生物技術的進步以及對更高效和更適合人類的熱原檢測方法的需求，促使 MAT 在北美得到廣泛採用。
  • 預計亞太地區將成長最快，預測期內 2025-2030 年的複合年成長率為 17.3%，製藥和生物技術領域將快速進步。這在很大程度上是由於中國、日本和印度等國家對生技藥品、疫苗和聯合療法的需求不斷成長。這些國家的監管機構擴大採用 MAT 作為傳統動物試驗的首選替代方案，以符合全球道德標準。此外，對病人安全的日益關注以及對更高效、更人性化的檢測方法的需求正在推動 MAT 的採用。該地區不斷擴大的醫療保健基礎設施進一步支持了 MAT 不斷成長的市場影響。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章單核細胞活化測試市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 單核細胞活化測試市場分析工具
    • 產業分析 – 波特五力分析
    • PESTEL 分析
    • 定價分析

第 4 章單核細胞活化測試市場：產品、估計與趨勢分析

  • 全球單核細胞活化測試市場：產品儀表板
  • 全球單核細胞活化測試市場：產品變異分析
  • 全球單核細胞活化測試市場（按產品和收益）
  • 單核細胞活化檢測套件
  • 試劑

第 5 章 單核細胞活化測試市場：按應用進行的估計和趨勢分析

  • 全球單核細胞活化測試市場：應用儀表板
  • 全球單核細胞活化測試市場：應用趨勢分析
  • 全球單核細胞活化測試市場（按應用和收益）
  • 藥物開發
  • 疫苗研發
  • 醫療設備測試
  • 其他

第6章 單核球活化測試市場來源、估計與趨勢分析

  • 全球單核細胞活化測試市場：來源儀表板
  • 全球單核細胞活化測試市場：來源變異分析
  • 全球單核細胞活化測試市場（依來源、收益）
  • 基於PBMC
  • 基於細胞株

7. 單核球活化測試市場：最終用途、估計與趨勢分析

  • 全球單核細胞活化測試市場：最終用途儀表板
  • 全球單核細胞活化測試市場：最終用途變異分析
  • 全球單核細胞活化測試市場（按最終用途和收益）
  • 製藥業
  • 生技產業
  • 醫療設備業
  • 其他

第 8 章單核細胞活化測試市場按產品、來源、應用、最終用途、區域、估計和趨勢分析

  • 區域控制面板
  • 市場規模、預測趨勢分析，2018-2030
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商概況
    • 主要經銷商及通路夥伴名單
    • 2024 年主要企業的市場佔有率分析
    • Lonza Group
    • Charles River Laboratories
    • Bio-Rad Laboratories
    • Seikagaku Corporation
    • Hyglos GmbH
    • Hyglos GmbH
    • Thermo Fisher Scientific
    • MAT BioTech
    • Eurofins Scientific
Product Code: GVR-4-68040-510-0

Monocyte Activation Test Market Growth & Trends:

The global monocyte activation test market size is expected to reach USD 1.45 billion by 2030, registering a CAGR of 15.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is driven by several key factors. Increasing regulatory pressure to replace animal testing with more ethical, human-relevant in vitro methods is a major driver. MAT's ability to provide accurate pyrogen detection using human immune cells makes it an attractive alternative to traditional endotoxin tests. The growing demand for biologics, vaccines, and complex pharmaceuticals further fuels MAT adoption, as safety is critical in these products. Additionally, advancements in biotechnology and the increasing emphasis on patient safety and quality control in drug development are contributing to the market's growth.

Technological innovations are significantly driving the growth of the Monocyte Activation Test (MAT) market. One of the key advancements is the development of more efficient and reproducible cell culture systems, particularly the use of immortalized human cell lines like THP-1 and U937 cells. These cell lines enhance the accuracy and consistency of MAT, making it a more reliable alternative to traditional animal testing methods. The ability to simulate the human immune response with these cell lines has improved the sensitivity of MAT, allowing for better detection of pyrogens, including both endotoxins and non-endotoxins.

Another innovation is the automation of MAT processes, which has streamlined testing workflows and reduced the time required to obtain results. Automated systems for preparing and analyzing MAT samples have increased throughput, making it more feasible for large-scale pharmaceutical and biotechnology companies to incorporate MAT into their quality control processes. Minerva Biolabs' next-generation MAT system, the NAT-MAT, represents a significant advancement in pyrogen testing. By utilizing digital PCR to measure the gene expression of IL-1B and TNF-a, the NAT-MAT provides highly sensitive and reliable results for detecting both endotoxin and non-endotoxin pyrogens. This system is optimized for fast testing, making it suitable for in-process control and final release testing of medicinal products, in line with Ph. Eur. 2.6.30 standards.

The key innovation in the NAT-MAT(R) lies in the parallel measurement of two cytokines alongside a housekeeping gene, which improves the accuracy of results. The housekeeping gene serves a dual purpose: it acts as a quality control for both the extraction process and cell density, ensuring the assay functions reliably across different cell densities. Additionally, the automated analysis through Minerva Biolabs' specialized software streamlines the process, ensuring compliance with regulatory requirements while enhancing testing efficiency.

This technology provides a significant improvement over traditional pyrogen testing methods by offering a more comprehensive and precise approach to ensuring the safety of pharmaceutical and biotechnological products. For example, companies like Lonza Group and Charles River Laboratories have integrated advanced cell culture technologies and automated systems into their MAT offerings, improving efficiency and scalability. Furthermore, advancements in high-throughput screening technologies have enabled faster and more cost-effective pyrogen testing, allowing MAT to be used in drug development and vaccine production more widely. These technological innovations continue to enhance MAT's adoption, making it an essential tool for ensuring the safety and efficacy of pharmaceutical and biotechnological products.

Monocyte Activation Test Market Report Highlights:

  • Based on product, MAT Kits segment accounted for largest revenue share of 63.7% in 2024. The MAT Kits segment is experiencing growth due to the increasing demand for reliable, human-relevant pyrogen testing methods. A key driving factor is the growing regulatory pressure to replace animal testing with in vitro alternatives. MAT kits offer a precise and ethical solution by using human immune cells to detect endotoxins and non-endotoxin pyrogens, ensuring the safety of pharmaceutical products. Additionally, the rising prevalence of biologics, vaccines, and complex drug formulations is driving the demand for MAT kits, as these products require stringent safety testing before reaching the market. The convenience and accuracy of MAT kits further boost their adoption.
  • Based on source, PBMC dominated the market and accounted for the largest share of 62.7% in 2024, due to the increasing demand for human-based, ethical alternatives to animal testing. PBMCs, which include monocytes, are critical for detecting pyrogens as they closely mimic the human immune response. This human-relevant testing method is gaining favor due to its ability to provide more accurate and reproducible results compared to traditional animal models. Additionally, the rise in biologic drug development, vaccines, and regulatory pressures to replace animal testing with in vitro methods further drives the adoption of PBMC-based MAT testing.
  • Based on application, drug development dominated the market and accounted for the largest share of 40.6% in 2024, due to increasing demand for accurate and reliable pyrogen testing methods. As the pharmaceutical industry develops more complex biologics and vaccines, ensuring product safety through rigorous testing is crucial. MAT provides an in vitro, human-relevant approach to detect endotoxins and non-endotoxin pyrogens, replacing traditional animal testing methods. Regulatory bodies like the FDA and EMA endorse MAT as a valid alternative, further promoting its adoption in drug development. The growing focus on patient safety, regulatory compliance, and the need for faster testing methods are key driving factors.
  • Based on end use, pharmaceutical industry segment is dominated the end use segments with the largest market share of 56.3% in 2024. The market growth is fueled by factors such as increasing need for reliable pyrogen testing in drug development and manufacturing. As the industry focuses on producing biologics, vaccines, and other complex therapeutic products, ensuring their safety is paramount. MAT, with its ability to detect endotoxins and non-endotoxin pyrogens using human immune cells, provides an accurate and ethical alternative to traditional animal testing. Regulatory agencies like the FDA and EMA support MAT's use, driving its adoption. The growing demand for safer, faster, and more efficient testing methods in pharmaceutical production is a key factor fueling MAT's market growth.
  • North America dominated the global market, primary driver is the region's stringent regulatory environment, with agencies like the FDA and Health Canada increasingly endorsing MAT as a reliable and ethical alternative to traditional animal testing. The demand for MAT is also fueled by the growing biologics and vaccine sectors, where ensuring product safety is crucial. Additionally, the rising focus on patient safety, advancements in biotechnology, and the need for more efficient and human-relevant pyrogen testing methods are contributing to the widespread adoption of MAT in North America.
  • Asia Pacific region is expected to witness fastest growth with a CAGR of 17.3% over the forecast period from 2025 to 2030, rapid advancements in the pharmaceutical and biotechnology sectors. The growing demand for biologics, vaccines, and complex therapeutics in countries like China, Japan, and India is a major factor. Regulatory authorities in these countries are increasingly adopting MAT as a preferred alternative to traditional animal testing, aligning with global ethical standards. Additionally, the rising focus on patient safety and the need for more efficient, human-relevant testing methods are driving MAT adoption. The region's expanding healthcare infrastructure further supports MAT's growing market presence.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Source
    • 1.2.3. Application
    • 1.2.4. End-use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and source outlook
    • 2.2.2. Application and end use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Monocyte activation test (MAT) Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing demand for safer and more accurate alternatives to LAL (Limulus Amebocyte Lysate) test
      • 3.2.1.2. Rising regulatory requirements for medical devices and pharmaceuticals
      • 3.2.1.3. Growing adoption of in vitro testing methods
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High initial setup costs
      • 3.2.2.2. Limited standardization and adoption across all regulatory frameworks
  • 3.3. Monocyte activation test (MAT) Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis

Chapter 4. Monocyte activation test (MAT) Market: Product Estimates & Trend Analysis

  • 4.1. Global Monocyte activation test (MAT) Market: Product Dashboard
  • 4.2. Global Monocyte activation test (MAT) Market: Product Movement Analysis
  • 4.3. Global Monocyte activation test (MAT) Market by Product, Revenue
  • 4.4. MAT Kits
    • 4.4.1. MAT kits market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Reagents
    • 4.5.1. Reagents market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Monocyte activation test (MAT) Market: Application Estimates & Trend Analysis

  • 5.1. Global Monocyte activation test (MAT) Market: Application Dashboard
  • 5.2. Global Monocyte activation test (MAT) Market: Application Movement Analysis
  • 5.3. Global Monocyte activation test (MAT) Market by Application , Revenue
  • 5.4. Drug Development
    • 5.4.1. Drug Development market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Vaccine Development
    • 5.5.1. Vaccine Development market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Medical Device Testing
    • 5.6.1. Medical Device Testing market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Monocyte activation test (MAT) Market: Source Estimates & Trend Analysis

  • 6.1. Global Monocyte activation test (MAT) Market: Source Dashboard
  • 6.2. Global Monocyte activation test (MAT) Market: Source Movement Analysis
  • 6.3. Global Monocyte activation test (MAT) Market by Source, Revenue
  • 6.4. PBMC Based
    • 6.4.1. PBMC Based market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Cell Line Based
    • 6.5.1. Cell Line Based market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Monocyte activation test (MAT) Market: End use Estimates & Trend Analysis

  • 7.1. Global Monocyte activation test (MAT) Market: End use Dashboard
  • 7.2. Global Monocyte activation test (MAT) Market: End use Movement Analysis
  • 7.3. Global Monocyte activation test (MAT) Market by End use, Revenue
  • 7.4. Pharmaceutical Industry
    • 7.4.1. Pharmaceutical Industry market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Biotechnology Industry
    • 7.5.1. Biotechnology Industry market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Medical Device Industry
    • 7.6.1. Medical Device Industry Analysis market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Others
    • 7.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Monocyte activation test (MAT) Market: Regional Estimates & Trend Analysis by Product, Source, Application and Methodology

  • 8.1. Regional Dashboard
  • 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.3. North America
    • 8.3.1. U.S.
      • 8.3.1.1. Key country dynamics
      • 8.3.1.2. Regulatory framework/ reimbursement structure
      • 8.3.1.3. Competitive scenario
      • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.2. Canada
      • 8.3.2.1. Key country dynamics
      • 8.3.2.2. Regulatory framework/ reimbursement structure
      • 8.3.2.3. Competitive scenario
      • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.3.3. Mexico
      • 8.3.3.1. Key country dynamics
      • 8.3.3.2. Regulatory framework/ reimbursement structure
      • 8.3.3.3. Competitive scenario
      • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4. Europe
    • 8.4.1. UK
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework/ reimbursement structure
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.2. Germany
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework/ reimbursement structure
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.3. France
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework/ reimbursement structure
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.4. Italy
      • 8.4.4.1. Key country dynamics
      • 8.4.4.2. Regulatory framework/ reimbursement structure
      • 8.4.4.3. Competitive scenario
      • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.5. Spain
      • 8.4.5.1. Key country dynamics
      • 8.4.5.2. Regulatory framework/ reimbursement structure
      • 8.4.5.3. Competitive scenario
      • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.6. Norway
      • 8.4.6.1. Key country dynamics
      • 8.4.6.2. Regulatory framework/ reimbursement structure
      • 8.4.6.3. Competitive scenario
      • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.7. Sweden
      • 8.4.7.1. Key country dynamics
      • 8.4.7.2. Regulatory framework/ reimbursement structure
      • 8.4.7.3. Competitive scenario
      • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.4.8. Denmark
      • 8.4.8.1. Key country dynamics
      • 8.4.8.2. Regulatory framework/ reimbursement structure
      • 8.4.8.3. Competitive scenario
      • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5. Asia Pacific
    • 8.5.1. Japan
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework/ reimbursement structure
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.2. China
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/ reimbursement structure
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.3. India
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/ reimbursement structure
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.4. Australia
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/ reimbursement structure
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.5. South Korea
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework/ reimbursement structure
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.5.6. Thailand
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework/ reimbursement structure
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. Latin America
    • 8.6.1. Brazil
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework/ reimbursement structure
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.6.2. Argentina
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/ reimbursement structure
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. MEA
    • 8.7.1. South Africa
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework/ reimbursement structure
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.2. Saudi Arabia
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/ reimbursement structure
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.3. UAE
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/ reimbursement structure
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 8.7.4. Kuwait
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/ reimbursement structure
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2024
    • 9.3.4. Lonza Group
      • 9.3.4.1. Company overview
      • 9.3.4.2. Financial performance
      • 9.3.4.3. Product benchmarking
      • 9.3.4.4. Strategic initiatives
    • 9.3.5. Charles River Laboratories
      • 9.3.5.1. Company overview
      • 9.3.5.2. Financial performance
      • 9.3.5.3. Product benchmarking
      • 9.3.5.4. Strategic initiatives
    • 9.3.6. Bio-Rad Laboratories
      • 9.3.6.1. Company overview
      • 9.3.6.2. Financial performance
      • 9.3.6.3. Product benchmarking
      • 9.3.6.4. Strategic initiatives
    • 9.3.7. Seikagaku Corporation
      • 9.3.7.1. Company overview
      • 9.3.7.2. Financial performance
      • 9.3.7.3. Product benchmarking
      • 9.3.7.4. Strategic initiatives
    • 9.3.8. Hyglos GmbH
      • 9.3.8.1. Company overview
      • 9.3.8.2. Financial performance
      • 9.3.8.3. Product benchmarking
      • 9.3.8.4. Strategic initiatives
    • 9.3.9. Hyglos GmbH
      • 9.3.9.1. Company overview
      • 9.3.9.2. Financial performance
      • 9.3.9.3. Product benchmarking
      • 9.3.9.4. Strategic initiatives
    • 9.3.10. Thermo Fisher Scientific
      • 9.3.10.1. Company overview
      • 9.3.10.2. Financial performance
      • 9.3.10.3. Product benchmarking
      • 9.3.10.4. Strategic initiatives
    • 9.3.11. MAT BioTech
      • 9.3.11.1. Company overview
      • 9.3.11.2. Financial performance
      • 9.3.11.3. Product benchmarking
      • 9.3.11.4. Strategic initiatives
    • 9.3.12. Eurofins Scientific
      • 9.3.12.1. Company overview
      • 9.3.12.2. Financial performance
      • 9.3.12.3. Product benchmarking
      • 9.3.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Monocyte activation test (MAT) market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 5 North America Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 6 North America Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 7 U.S. Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 8 U.S. Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 9 U.S. Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 10 U.S. Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Canada Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 12 Canada Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 13 Canada Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 14 Canada Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Mexico Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 16 Mexico Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 17 Mexico Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 18 Mexico Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe Monocyte activation test (MAT) market, by region, 2018 - 2030 (USD Million)
  • Table 20 Europe Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 21 Europe Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 22 Europe Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 23 Europe Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Germany Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 25 Germany Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 26 Germany Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 27 Germany Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 28 UK Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 29 UK Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 30 UK Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 31 UK Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 32 France Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 33 France Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 34 France Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 35 France Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 36 Italy Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 37 Italy Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 38 Italy Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 39 Italy Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 40 Spain Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 41 Spain Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 42 Spain Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 43 Spain Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Denmark Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 45 Denmark Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 46 Denmark Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 47 Denmark Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 48 Sweden Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 49 Sweden Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 50 Sweden Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 51 Sweden Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Norway Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 53 Norway Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 54 Norway Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 55 Norway Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Asia Pacific Monocyte activation test (MAT) market, by region, 2018 - 2030 (USD Million)
  • Table 57 Asia Pacific Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 58 Asia Pacific Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 59 Asia Pacific Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 60 Aisa Pacific Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 61 China Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 62 China Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 63 China Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 64 China Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Japan Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 66 Japan Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 67 Japan Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 68 Japan Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 69 India Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 70 India Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 71 India Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 72 India Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 73 South Korea Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 74 South Korea Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 75 South Korea Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 76 South Korea Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 77 Australia Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 78 Australia Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 79 Australia Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 80 Australia Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 81 Thailand Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 82 Thailand Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 83 Thailand Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 84 Thailand Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 85 Latin America Monocyte activation test (MAT) market, by region, 2018 - 2030 (USD Million)
  • Table 86 Latin America Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 87 Latin America Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 88 Latin America Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 89 Latin America Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 90 Brazil Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 91 Brazil Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 92 Brazil Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 93 Brazil Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 94 Argentina Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 95 Argentina Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 96 Argentina Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 97 Argentina Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 98 MEA Monocyte activation test (MAT) market, by region, 2018 - 2030 (USD Million)
  • Table 99 MEA Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 100 MEA Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 101 MEA Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 102 MEA Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 103 South Africa Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 104 South Africa Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 105 South Africa Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 106 South Africa Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 107 Saudi Arabia Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 108 Saudi Arabia Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 109 Saudi Arabia Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 110 Saudi Arabia Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 111 UAE Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 112 UAE Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 113 UAE Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 114 UAE Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)
  • Table 115 Kuwait Monocyte activation test (MAT) market, by product, 2018 - 2030 (USD Million)
  • Table 116 Kuwait Monocyte activation test (MAT) market, by source, 2018 - 2030 (USD Million)
  • Table 117 Kuwait Monocyte activation test (MAT) market, by application, 2018 - 2030 (USD Million)
  • Table 118 Kuwait Monocyte activation test (MAT) market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Monocyte activation test (MAT) market: market outlook
  • Fig. 14 Monocyte activation test (MAT) competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Monocyte activation test (MAT) market driver impact
  • Fig. 18 Monocyte activation test (MAT) market restraint impact
  • Fig. 19 Monocyte activation test (MAT) market: Product movement analysis
  • Fig. 20 Monocyte activation test (MAT) market: Product outlook and key takeaways
  • Fig. 21 MAT Kits market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Reagents estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Monocyte activation test (MAT) market: Application movement analysis
  • Fig. 24 Monocyte activation test (MAT) market: Application outlook and key takeaways
  • Fig. 25 Drug Development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Vaccine Development estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Medical Device Testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Others estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Monocyte activation test (MAT) market: Source movement analysis
  • Fig. 30 Monocyte activation test (MAT) market: Source outlook and key takeaways
  • Fig. 31 PBMC Based market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Cell Line Based estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Monocyte activation test (MAT) market: End use movement analysis
  • Fig. 34 Monocyte activation test (MAT) market: End use outlook and key takeaways
  • Fig. 35 Pharmaceutical Industry market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Biotechnology Industry estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Medical Device Industry market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Others estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Global Monocyte activation test (MAT) market: Regional movement analysis
  • Fig. 40 Global Monocyte activation test (MAT) market: Regional outlook and key takeaways
  • Fig. 41 Global Monocyte activation test (MAT) market share and leading players
  • Fig. 42 North America, by country
  • Fig. 43 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. key country dynamics
  • Fig. 45 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Canada key country dynamics
  • Fig. 47 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Mexico key country dynamics
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 UK key country dynamics
  • Fig. 52 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Germany key country dynamics
  • Fig. 54 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 France key country dynamics
  • Fig. 56 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Italy key country dynamics
  • Fig. 58 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Spain key country dynamics
  • Fig. 60 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Denmark key country dynamics
  • Fig. 62 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Sweden key country dynamics
  • Fig. 64 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Norway key country dynamics
  • Fig. 66 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 China key country dynamics
  • Fig. 69 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Japan key country dynamics
  • Fig. 71 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 India key country dynamics
  • Fig. 73 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Thailand key country dynamics
  • Fig. 75 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 South Korea key country dynamics
  • Fig. 77 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Australia key country dynamics
  • Fig. 79 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Brazil key country dynamics
  • Fig. 82 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Argentina key country dynamics
  • Fig. 84 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 South Africa key country dynamics
  • Fig. 87 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Saudi Arabia key country dynamics
  • Fig. 89 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 UAE key country dynamics
  • Fig. 91 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Kuwait key country dynamics
  • Fig. 93 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Market share of key market players- Monocyte activation test (MAT) market